Last close As at 05/08/2026
USD48.24
▲ 3.33 (7.41%)
Market capitalisation
USD20,120m
Research: Metals & Mining
The revised 2026 preliminary economic assessment (PEA) for La Colorada redefines the project as an integrated 15,000tpd operation, significantly lowering the initial capital spend and execution risk compared to the 2023 standalone study. By transitioning to a selective sub-level open stoping mining method, Pan American Silver (PAAS) has reduced pre-production capital to
| Year end | Revenue ($m) | EBITDA ($m) | EPS ($) | DPS ($) | EV/EBITDA (x) | Yield (%) |
|---|---|---|---|---|---|---|
| 12/24 | 2,818.9 | 1,028.6 | 0.80 | 0.40 | 19.9 | 0.8 |
| 12/25 | 3,619.1 | 1,817.0 | 2.53 | 0.54 | 11.3 | 1.0 |
| 12/26e | 4,821.0 | 3,047.4 | 3.78 | 0.68 | 6.7 | 1.3 |
| 12/27e | 4,508.5 | 2,830.8 | 3.50 | 0.68 | 7.2 | 1.3 |
The 2026 study moves away from the 50,000tpd bulk sub-level cave approach in favour
of an integrated mine plan that co-develops 13,000tpd of high-grade skarn with 2,000tpd
of vein material. This shift prioritises feed grades that exceed the 2023 study by
84% for silver, 45% for zinc, and 54% for lead, supporting the "grade over volume"
approach. The project envisages a 37-year mine life and is expected to be fully self-funded
through operating cash flows over a six-year construction period (2026–31). Initial
capital investment is estimated at
The revised PEA values the Skarn project at an after-tax NPV (5%) of
The revised 2026 PEA on the La Colorada Skarn project has materially reshaped the
development pathway that was initially proposed in the 2023 technical study. Rather
than advancing the large-scale, standalone 50,000tpd skarn operation based on a sub-level
cave (SLC) mining method, the company has pivoted towards a more selective development
of an integrated project. The revised mine plan combines production from higher-grade
portions of the skarn mineral resource with newly identified high-grade veins in the
eastern Candelaria area, alongside a portion of the existing vein resources. The project
is now expected to process feed grades that significantly exceed the 2023 study (silver
+84%, zinc +45%, lead +54%), effectively emphasising the ‘grade over volume’ approach.
The shift to a more selective 15ktpd sub-level/long-hole open stoping mining method
materially lowers the execution risk and reduces the project’s peak capital intensity,
with the pre-production capital cost falling to
The integrated mine plan extends the project’s life to 37 years following commissioning of a new 15,000tpd plant that will process material from both vein and skarn deposits. During the first five years of operation post ramp up (2034–38), the project is expected to produce on average 19.1Moz of silver, 246kt of zinc and 154kt of lead per year on a combined basis. The 2023 study envisaged production of 17.2Moz of silver, 427kt of zinc and 218kt of lead over the initial 10 years of operation, with a mine life of 17 years. The revised development plan would position the project as one of the largest primary silver mines globally, in terms of both mineral resources and future production, with further upside potential from recent drilling of 93,700m not yet reflected in current mineral resource estimates.
The revised PEA outlines a highly competitive cost structure, with industry-leading
silver costs underpinned by substantial base metal by-product credits. At base case
commodity prices of
The revised PEA adopts a selective sub-level open stoping (SLOS) mining method with transverse sequencing and paste backfill for the skarn deposit, prioritising higher-grade extraction while reducing the geotechnical risks associated with the bulk caving approach proposed earlier. This mining method ensures the preservation of existing mine infrastructure, allowing the current La Colorada vein mine to operate concurrently with the development of the skarn deposit.
The integrated mine plan envisions a nominal production rate of 15,000tpd. This throughput comprises 13,000tpd from high-grade skarn mineralisation and 2,000tpd from the vein mine. Initial underground access to the skarn mineral resources will be established via a decline from the existing 588 level, with preparatory work scheduled to commence in 2026. Long-term hoisting and ventilation requirements for the expanded mine will be supported by a 1,480m deep production shaft and a corresponding 1,400m deep ventilation shaft. The infrastructure is specifically designed to manage the region's high geothermal gradient and underground temperatures through an active heat management system. Notably, no additional permitting is required for the 588-level ramp decline, though permit applications will be submitted for other project components, including the new shafts, processing plant and tailings facility expansions.
Central to the project's expansion is the construction of a new 15,000tpd conventional
selective flotation plant, timed to coincide with the initial production ramp-up from
the skarn deposit in 2032. The facility will be located adjacent to existing infrastructure
and is designed to process the total commingled output of the expanded mine. The circuit
is expected to produce high-quality concentrates grading approximately 61% lead (with
c 1,800g/t silver) and 59% zinc (with c 140g/t silver). Life of mine recoveries are
estimated at 89.7% for silver, 93.4% for zinc and 87.7% for lead, with 77.8% of the
silver reporting to the lead concentrate. The project’s total initial capital estimate
of
The expanded La Colorada mine is underpinned by a substantial resource base effective
30 June 2025. The skarn deposit contains an indicated mineral resource of 265.4Mt
grading 36g/t Ag, 2.85% Zn and 1.37% Pb, representing 309Moz of contained silver.
This is supplemented by 61.7Mt of inferred skarn resources at 30g/t Ag (59 Moz Ag).
The project also integrates significant high-grade vein mineralisation, including
15.3Mt of inferred resources at 297g/t Ag (146.5Moz Ag). Importantly, the project’s
resource model was calculated using a conservative silver price of
Significant exploration upside represents an important value catalyst for the project, with approximately 93,700m of recent diamond drilling excluded from the current resource models. This drilling includes 45,700m targeting the skarn and 48,000m in the vein deposit, completed post-data cut-off. Key areas of focus include:
The revised PEA values the standalone Skarn project at an NPV (5%) of
Based on the valuation sensitivity analysis provided in the PEA announcement – which
estimates the project’s value at
Incorporating the Skarn project into our group NPV increases our valuation of PAAS
from
General disclaimer and copyright
This report has been commissioned by Pan American Silver and prepared and issued by Edison, in consideration of a fee payable by Pan American Silver. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.
Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.
Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.
No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.
Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.
Copyright 2026 Edison Investment Research Limited (Edison).
Australia
Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.
New Zealand
The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.
United Kingdom
This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or sol icitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.
This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.
United States
Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.
London │ New York │ Frankfurt
20 Red Lion Street
London, WC1R 4PS
United Kingdom
Research: Healthcare
Cereno Scientific has reported encouraging initial observations from the 12-month Expanded Access Program (EAP), reinforcing CS1’s favourable safety and tolerability profile across longer-term use. While based on a small dataset (n=10; six completing 12 months), we view the findings as supportive of the upcoming Phase IIb plans,while also contributing to de-risking of the regulatory pathway and supporting ongoing partnering discussions. This is particularly relevant in pulmonary arterial hypertension, where current therapies, including vasodilators (in particular prostacyclins) and newer agents such as activin signalling inhibitors (such as Winrevair), are often limited by tolerability, affecting compliance and treatment persistence. Further EAP data (potentially durability of response and/or other efficacy signals) and results from the Fluidda imaging sub-study are expected in Q226 and should help refine the clinical profile further. Upcoming catalysts include first patient dosing in the Phase IIb study (expected June 2026), which remains the key value driver. We leave our estimates unchanged.